ArticleBiomaterials2015
Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism.
Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 75 citations in OpenAlex.
- Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer.Acta pharmaceutica Sinica. B · 2026Review
- Physicochemical Stability and Cross-Context Validation of PEGylated Human Serum Albumin Nanoparticles for Dual Neurotrophin Delivery in the Rabbit Eye and Oxidative Stress Models.International journal of nanomedicine · 2026Article
- Ultrabright NIR-II Nanoprobes forACS nanoscience Au · 2025Article
- Wolf in Sheep's Clothing: Taming Cancer's Resistance with Human Serum Albumin?International journal of nanomedicine · 2025Review
- Facile construction of manganese-based contrast agent with highRegenerative biomaterials · 2025Article
- GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs.Frontiers in pharmacology · 2024Review
- BSA modification of bacterial surface: a promising anti-cancer therapeutic strategy.BMC microbiology · 2023Article
- Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer.Journal of nanobiotechnology · 2022Article
- In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer.Drug delivery and translational research · 2020Article
- Enhancing cancer immunotherapy with nanomedicine.Nature reviews. Immunology · 2020Review
- Albumin-Modified Melanin-Silica Hybrid Nanoparticles Target Breast Cancer Cells via a SPARC-Dependent Mechanism.Frontiers in bioengineering and biotechnology · 2020Article
- Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Insight into the preformed albumin corona onAsian journal of pharmaceutical sciences · 2019Article
- Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.Drug delivery and translational research · 2018Review
- Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors.Biomaterials · 2018Article
- Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies.Acta pharmaceutica Sinica. B · 2018Review
- Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.Advanced drug delivery reviews · 2018Review
- Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals.Molecular pharmaceutics · 2018Article
- Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment.Pharmaceutical research · 2017Article
- Albumin-coated nanocrystals for carrier-free delivery of paclitaxel.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Cellax, a polymer-docetaxel (DTX) conjugate that self-assembled into 120 nm particles, displayed significant enhancements in safety and efficacy over native DTX across a number of primary and metastatic tumor models. Despite these exciting preclinical data, the underlying mechanism of delivery of Cellax remains elusive. Herein, we demonstrated that serum albumin efficiently adsorbed onto the Cellax particles with a 4-fold increased avidity compared to native DTX, and the uptake of Cellax by cells was primarily driven by an albumin and SPARC (secreted protein acidic and rich in cysteine, an albumin binder) dependent internalization mechanism. In the SPARC-positive cells, a >2-fold increase in cellular internalization of Cellax was observed in the presence of albumin. In the SPARC-negative cells, no difference in Cellax internalization was observed in the presence or absence of albumin. Evaluation of the internalization mechanism using endocytotic inhibitors revealed that Cellax was internalized predominantly via a clathrin-mediated endocytotic mechanism. Upon internalization, it was demonstrated that Cellax was entrapped within the endo-lysosomal and autophagosomal compartments. Analysis of the tumor SPARC level with tumor growth inhibition of Cellax in a panel of tumor models revealed a positive and linear correlation (R(2) > 0.9). Thus, this albumin and SPARC-dependent pathway for Cellax delivery to tumors was confirmed both in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.